NGL Fine Chem LtdQ1 FY26Pharmaceuticals & Biotechnology

NGL Fine Chem Ltd

Q1 FY26 Earnings Call Analysis

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Order

N/A

Capex

Yes

1 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

→Revenue growth has shown strong momentum with a 36% increase in FY26, driven by broad-based volume growth across products and geographies.
→Volume growth is stable with demand recovery confirmed over the last three quarters, providing confidence for maintaining or improving current run rates.
→New plant expansions are expected to add up to Rs. 350 crores in turnover over the next 3-4 years.
→Regulated market sales (Europe starting FY27, US from FY28) will contribute meaningfully from FY28 onwards, though peak contributions are still to be crystallized.
→The company aims to stabilize at a quarterly run rate of approx. Rs. 150 crore, with potential to exceed it over time.
→Continued addition of 9-10 new products annually supports diversified growth.
→Uptake in Latin America, Africa, and Southeast Asia markets further supports volume increases.
→Organic growth plus capacity expansions position the company well for sustained revenue and volume growth over the next 2-4 years.

Margin guidance

Category 3

→FY26 showed strong recovery with 36% revenue growth, 114% EBITDA increase, and 128% PAT growth.
→Volume-led growth and capacity expansions are key growth drivers.
→New plant Phase I is operational; Phase II commissioning expected early Q2 FY27, commercial production H2 FY27.
→Partial price pass-through achieved; further margin improvement expected as commodity cost pressures stabilize.
→EBITDA margin guidance remains 15%-18%; new regulated market segments could add 3%-5% margin premium.
→Regulated market sales to start contributing meaningfully from FY28 onwards.
→Peak revenue potential from new expansion estimated at Rs. 350 crores over 3-4 years.
→Overall, maintaining cautious optimism with stabilized quarterly run rate targets around Rs.150 crore and anticipation of continued broad-based demand and customer additions.
→Management expects steady revenue and margin growth aligned with capacity scaling and market expansion over next 2-3 years.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no explicit mention of any current or planned new fundraising through debt or equity in the transcript.
→The company has completed CAPEX of around Rs. 182 crores for capacity expansion in Q4, with total project CAPEX estimated at about Rs. 210 crores.
→Going forward, annual CAPEX is expected to be around Rs. 15 to 20 crores.
→The management indicated funding the entire increase in costs internally without additional borrowing.
→Debt outstanding is approximately Rs. 100 crores currently.
→Management has not provided details on future capital allocation plans including dividends or buybacks but is focused on repaying debt and supporting ongoing CAPEX from internal cash flows.
→No announcements were made regarding equity fundraising or fresh debt issuance during the call.

Order book

The transcript provided in the document does not explicitly mention the current or expected order book or pending orders for NGL Fine-Chem Limited. However, the following relevant points related to future growth and demand can be noted: - Expect revenue run rate to stabilize around Rs. 150 crore quarterly, with new capacity utilization increasing over next 1-2 quarters. - Growth and demand stable for past three quarters, indicating strong order flow continuity. - Expansion plans anticipate generating Rs. 350 crore turnover from the new plant over the next 3-4 years. - Regulated market sales expected to start contributing significantly from FY’28 onwards. - Product registrations and approvals (CEPs and DMS) ongoing to boost market access. - Demand is broad-based across geographies including Latin America, Europe, Africa, and Southeast Asia. No specific quantitative order book or pending orders numbers disclosed in the transcript.

Capex plans

Yes

→Total planned CAPEX for the ongoing expansion program is ₹210 crores, with ₹182.75 crores invested up to Q4 FY26.
→Phase II Greenfield expansion at Tarapur faced delays due to gas and labor shortages; commissioning rescheduled from Q1 FY27 to early Q2 FY27.
→Commercial production for Phase II is expected to start from H2 FY27, as previously guided.
→Post project completion, annual CAPEX is expected to be around ₹15-20 crores.
→No additional large-scale CAPEX currently planned beyond this expansion.
→Management is financing the cost increase internally, without additional borrowing.
→Peak utilization of new capacity is anticipated over the next 3-4 years.
→No forward-looking numbers shared on future strategic investments or dividend plans; management remains cautious on projections.

How does NGL Fine Chem Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1NGL Fine Chem Ltd

Rev 2Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Unlock with Pro

Want more stocks like NGL Fine Chem Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio